Mechanism of action of tetrahydro-N, N-dimethyl-5, 5-diphenyl-3-furanemethanamine, a putative nootropic, anti-epileptic and antidepressant compound;Mécanisme d'action de la tétrahydro-N, N-diméthyl-5, 5-diphényl-3-furaneméthanamine, un dérivé potentiellement nootrope, antiépileptique et antidépresseur

Annales Pharmaceutiques Francaises

Volumn 60, Issue 6, 2002, Pages 415-422

  Vamvakides A ^a,b  

^a Faculte de Medecine d'Athenes   (Greece)

^b NONE   (France)

Author keywords

5 diphenyl 3 furanemethanamine; Anticonvulsant; Antidepressant; Mechanism of action; N dimethyl 5; Nootropic; Tetrahydro N

Indexed keywords

AE 14; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; DRUG RECEPTOR; FURAN DERIVATIVE; LAMOTRIGINE; METHYLAMINE; MUSCARINIC M1 RECEPTOR AGONIST; NOOTROPIC AGENT; PHENYTOIN; SODIUM CHANNEL; TETRAHYDRO N,N DIMETHYL 5,5 DIPHENYL 3 FURANEMETHANAMINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; DRUG EFFECT; DRUG MECHANISM; ELECTRIC SHOCK; FORCED SWIMMING TEST; IMMOBILIZATION; MOUSE; NONHUMAN; RECEPTOR AFFINITY; TONIC SEIZURE;

ALZHEIMER DISEASE; ANIMALS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS; FURANS; HUMANS; MUSCARINIC AGONISTS; NOOTROPIC AGENTS; RECEPTOR, MUSCARINIC M1; RECEPTORS, MUSCARINIC;

EID: 0036864128     PISSN: 00034509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (76)

1. Kolocouris N, Fytas G, Brunet C, Luyckx M. Nouveaux aminoéthers et aminolactones. Synthèse et approche pharmacologique. Ann Pharm Fr 1985; 43: 257-64.
2. Foscolos GB, Kolocouris N, Fytas G, Marakos P, Pouli N, Vamvakidès A. Synthesis and pharmacological study of some new, β- (dialkylaminomethyl)-γ-butyrolactones and their tetrahydrofuran analogues. Farmaco 1996; 51: 19-26.
3. Vamvakidès A, Kolocouris N, Foscolos G, Fytas G, Papadopoulou-Daifoti Z, Pouli N. Tetrahydro-N, N-dimethyl-2, 2-diphenyl-3-furanemethanamine as anticonvulsant, anti-depressant and nootropic agent. Brevet PCT Int Appl WO 97 30, 983. Chem Abstracts 1997; 127: 248008 p. & Utilisation pharmacothérapeutique de deux dérivés tétrahydrofuraniques: tétrahydro-N, N-diméthyl-5, 5- diphényl-3-furaneméthanamine (AE14) et tétrahydro-N, N-diméthyl-2, 2-diphényl-3-furaneméthanamine (AE37). Brevet. 98 01 00 418 (Grèce).
4. Mondadori C, Etienne P: The effects of ACE-inhibitors on memory in mice. Psychopharmacology 1990; 100: 301-7 & How long does "memory consolidation" take? New compounds can improve retention performance, even if administered up to 24 hours after learning experience. Brain Res 1991; 555: 107-11.
5. Mondadori C, Etienne P: The effects of ACE-inhibitors on memory in mice. Psychopharmacology 1990; 100: 301-7 & How long does "memory consolidation" take? New compounds can improve retention performance, even if administered up to 24 hours after learning experience. Brain Res 1991; 555: 107-11.
6. Vamvakidès A. et coll. Résultats non Publiés: Évitement Passif Selon [4], Nage Forcée Selon [6] [68] et Convulsions Selon [13].
7. Porsolt RD, Bertin A, Jalfre M. Behavioral despair in mice: A primary screening test for antidepressants. Arch Int Pharmacodyn Therap 1977; 229: 327-36.
8. Borsini F, Meli A. Is the forced swimming test a suitable model for revealing a depressant activity? Psychopharmacology 1988; 94: 147-60.
9. Vaugeois JM, Pouhé D, Zuccaro F, Constentin J. Indirect dopamine agonists effects on despair test: Dissociation from hyperactivity. Pharmacol Biochem Behav 1996; 54: 235-9.
10. Greenamyre JT, Maragos EF, Albin RL, Penney JB, Young A. Glutamate transmission and toxicity in Alzheimer's disease. Prog Neuro-Psychopharmacol Biol Psychiatr 1988; 12: 421-30.
11. Francis PT, Sims NR, Procter AW, Bowen DM. Cortical neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer's disease. Investigative and therapeutic perspectives. J Neurochem 1993; 60: 1589-604.
12. Danysz W, Parsons CG, Bresink I, Quack G. Glutamate in CNS disorders. DN & P 1995; 8: 261-77 & 1998; 11: 523-69.
13. Danysz W, Parsons CG, Bresink I, Quack G. Glutamate in CNS disorders. DN & P 1995; 8: 261-77 & 1998; 11: 523-69.
14. Morris RGM, Anderson E, Lynch GS, Baudry M. Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. Nature 1986; 319: 774-6.
15. Peterson SL. Infusion of NMDA antagonists into the nucleus reticularis pontis oralis inhibits the maximal electroshock seizure response. Brain Res 1995; 702: 101-9 & The anticonvulsant activity of D-cycloserine is specific of tonic convulsions. Epilepsy Res 1993; 15: 141-8.
16. Peterson SL. Infusion of NMDA antagonists into the nucleus reticularis pontis oralis inhibits the maximal electroshock seizure response. Brain Res 1995; 702: 101-9 & The anticonvulsant activity of D-cycloserine is specific of tonic convulsions. Epilepsy Res 1993; 15: 141-8.
17. Hirsch SR, Indrajit D, Garey LJ, de Belleroche J. A pivotal role for glutamate in the pathogenesis of schizophrenia and its cognitive dysfunction. Pharmacol Biochem Behav 1997; 56: 797-802.
18. Muir JL. Acetylcholine, aging and Alzheimer's disease. Pharmacol Biochem Behav 1997; 56: 687-96.
19. Avery EE, Baker LD, Asthana S. Potential role of muscarinic agonists in Alzheimer's disease. Drugs & Aging 1997; 11: 450-9.
20. Löscher W. New visions in the pharmacology of anticonvulsion. Eur J Pharmacol 1998; 342: 1-13.
21. Dijk SN, Francis PT, Stratmann GC, Bowen DM. Cholinomimetics increase glutamate outflow via an action on the corticostriatal pathway: Implications for Alzheimer's disease. J Neurochem 1995; 65: 2165-9.
22. Marino MJ, Rouse ST, Levey AI, Potter LT, Conn PJ. Activation of the genetically defined ml muscarinic receptor potentiates N-methyl-D-asparate (NMDA) receptor currents in hippocampal pyramidal cells. Proc Natl Acad Sci USA 1998; 95: 11465-70.
23. Collingridge GL, Singer W. Excitatory amino acid receptors and synaptic plasticity. TIPS 1990; 11: 290-6.
24. Rogawski MA, Porter RJ. Antiepileptic drugs: Pharmacological mechanism and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol Rev 1990; 42: 224-86.
25. Voigt JP, Morgenstern E. Comparative effects of carbamazepine, phenytoin, diazepam and clonazepam on inhibitory avoidance learning. Psychopharmacology 1992; 108: 131-5.
26. Devinsky O. Cognitive and behavioral effects of antiepileptic drugs. Epilepsia (NY) 1995; 36 (Suppl. 2): S46-S65.
27. Perucca E. The new generation of antiepileptic drugs: Advantages and disadvantages. Br J Clin Pharmacol 1996; 42: 531-43.
28. Wong ICK, Tavernor SJ, Tavernor RME. Psychiatric adverse effects of anticonvulsant drugs. CNS Drugs 1997; 8: 492-509.
29. Meier E, Frederiksen K, Nielsen M, Lemböl HL, Pedersen H, Hyttel J. Pharmacological in vitro characterization of the arecoline bioisostere, Lu25-109-T, a muscarinic compound with M1-agonistic and M2/M3-antagonistic properties. Drug Dev Res 1997; 40: 1-16.
30. Levey AI. Immunological localization of m1-m5 muscarinic acetylcholine receptors in peripheral tissues and brain. Life Sci 1993; 52: 441-8.
31. Dörje F, Levey AI, Brann MR. Immunological detection of muscarinic receptor subtype proteins (m1-m5) in rabbit peripheral tissues. Mol Pharmacol 1991; 40: 459-62.
32. Freedman SB, Dawson GR, Iversen LL, Baker R, Hargreaves RJ. The design of novel muscarinic partial agonists that have functional selectivity in pharmacological preparations in vitro and reduced side-effect profile in vivo. Life Sci 1993; 52: 489-95.
33. Ensinger HA, Bechtel WD, Birke FW, Mendla KD, Mierau J, Speck G, et al. WAL2014FU (Talsaclidine): A preferentially neuron activating muscarinic agonist for the treatment of Alzheimer's disease. Drug Dev Res 1997; 40: 144-57.
34. Whitehouse PJ, Au KS. Cholinergic receptors in aging and Alzheimer's disease. Prog Neuro-Psychopharmacol Biol Psychiatry 1986; 10: 665-76.
35. Gill TM, Gallagher M. Evaluation of muscarinic M2 receptor sites in basal forebrain and brainstem cholinergic systems of behaviorally characterized young and aged Long-Evans rats. Neurobiol Aging 1998; 19: 217-25.
36. Richards MH. Rat hippocampal muscarinic autoreceptors are similar to the M2 (cardiac) subtype: Comparison with hippocampal M1, atrial M2, and ileal M3 receptors. Br J Pharmacol 1990; 99: 753-61.
37. Stillman MJ, Shukitt-Hale B, Kong RM, Levy A, Lieberman HR. Elevation of hippocampal extracellular acetylcholine levels by methoctramine. Brain Res Bull 1993; 32: 385-9.
38. Quirion R, Richard J, Wilson A. Muscarinic and nicotinic modulation of cortical acetylcholine release monitored by in vivo microdialysis in freely moving adult rats. Synapse (NY) 1994; 17: 92-100.
39. Soejima O, Katsuragi T, Furukawa T. Opposite modulation by muscarinic M1 and M3 receptors of acetylcholine release from guinea pig ileum as measured directly. Eur J Pharmacol 1993; 249: 1-6.
40. Fisher A. Muscarinic agonists for the treatment of Alzheimer's disease: Progress and perspectives. Expert Opin Invest Drugs 1997; 6: 1395-411.
41. Schwarz RD, Callahan MJ, Davis RE, Jaen JC, Tecle H. Development of M1 subtype selective muscarinic agonists for Alzheimer's disease: Translation of in vitro selectivity into in vivo efficacy. Drug Dev Res 1997; 40: 133-43.
42. Nitsch RM, Growdon JH. Role of neurotransmission in the regulation of amyloid β-protein precursor processing. Biochem Pharmacol 1994; 47: 1275-84.
43. Delapp N, Wu S, Belagaje R, Johnstone E, Little S, Shannon H et al. Effects of the M1 agonist xanomeline on processing of human β-amyloid precursor protein (FAD, Swedish mutant) transfered into chinese hamster ovarym1 cells. Biochem Biophys Res Commun 1998; 244: 156-60.
44. Ragsdale DS, Avoli M. Sodium channels as molecular targets for antiepileptic drugs. Brain Res Rev 1998; 26: 16-28.
45. Lang DG, Wang CM, Cooper BR. Lamotrigine, phenytoin and carbamazepine interactions on the sodium current present in N4TG1 mouse neuroblastoma cells. J Pharmacol Exp Ther 1993; 266: 829-35.
46. Tunnicliff G. Basis of the antiseizure action of phenytoin. Gen Pharmacol 1996; 27: 1091-7.
47. Probert AW, Borosky S, Marcoux FW, Taylor CP. Sodium channel modulators prevent oxygen and glucose deprivation injury and glutamate release in rat neocortical cultures. Neuropharmacology 1997; 36: 1031-8.
48. Toner CC, Stamford JA. Sodium channel blockade unmasks two temporally distinct mechanisms of striatal dopamine release during hypoxia/hypoglycemia in vitro. Neuroscience 1997; 81: 999-1007.
49. Vamvakidès A. Effets anticonvulsivant et anti-immobilité (nage forcée) de la tétrahydro-N, N-diméthyl-2, 2-diphé- nyl-3-furaneméthanamine (AE37): Mécanisme d'action commun? Ann Pharm Fr.
50. Browning RA. Role of the brain-stem reticular formation in tonic-clonic seizures: Lesion and pharmacological studies. Fed Proc 1985; 44: 2425-31.
51. Sanchez C, Meier E. Central and peripheral mediation of hypothermia, tremor and salivation induced by muscarinic agonists in mice. Pharmacol Toxicol 1993; 72: 262-7.
52. De la Vega MT, Nunez A, Arias-Montano JA. Muscarinic M1 and M3 receptors in rat striatum: A binding study. Arch Med Res 1997; 28: 493-7.
53. Sugita S, Uchimura N, Jiang G, North RA. Distinct muscarinic receptors inhibit release of γ-aminobutyric acid and excitatory amino acids in mammalian brain. Proc Natl Acad Sci USA 1991; 88: 2608-11.
54. Baghdoyan HA, Lydic R, Fleegal MA. M2 muscarinic autoreceptors modulate acetylcholine release in the medial reticular formation. J Pharmacol Exp Ther 1998; 286: 1446-52.
55. Mrzljak L, Levey AI, Belcher S, Goldman-Rakici PS. Localization of the M2 muscarinic acetylcholine receptor protein and mRNA in cortical neurons of the normal and cholinergically deafferented rhesus monkey. J Comp Neurol 1998; 390:112-32.
56. Rataud J, Debarnot F, Mary V, Pratt J, Stutzmann JM. Comparative study of voltage-sensitive sodium channel blockers in focal ischemia and electric convulsions in rodents. Neurosci Lett 1994; 172: 19-23.
57. Moghaddam B. Stress preferentially increases extraneuronal levels of excitatory amino acids in the prefrontal cortex: Comparison to hippocampus and basal ganglia. J Neurochem 1993; 60: 1650-7.
58. Nowak G, Redmond A, Mc Namara M, Paul IA. J. Swim stress increases the potency of glycine at the N-methyl-D-aspartate receptor complex. J Neurochem 1995; 64: 925-7.
59. Trullas R, Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant action. Eur J Pharmacol 1990; 185: 1-10.
60. Przegalinski E, Tatarczynska E, Deren-Wesolek A, Chojnacka-Wojcik E. Antidepressant-like effects of a partial agonist at strychnine-insensitive glycine receptors and a competitive NMDA receptor antagonist. Neuropharmacology 1997; 36: 31-7.
61. Vamvakidès A. La D-cyclosérine est active chez la souris adulte et inactive chez la Souris âgée dans le test de la nage forcée. Ann Pharm Fr 1998; 58: 209-12.
62. Vamvakidès A. Effets anticonvulsivant et anti-immobilité (nage forcée) de la tétrahydro-N, N-diméthyl-2, 2-diphé-nyl-3-furaneméthanamine (AE37). Ann Pharm Fr 2002; 60: 88-92.
63. Carlsson M, Carlsson A. Interactions between glutamatergic and monoaminergic systems within the basal ganglia. Implications for schizophrenia and Parkinson's disease. TINS 1990; 13: 272-6.
64. Paul IA, Nowak G, Layer RT, Popik P, Skolnick P. Adaptation of the N-methyl-D-aspartique receptor complex following chronic antidepressant treatments. J Pharmacol Exp Ther 1994; 269: 95-102.
65. Nowak G, Legutko B, Skolnick P, Popik P. Adaptation of cortical NMDA receptors by chronic treatment with specific serotonin reuptake inhibitors. Eur J Pharmacol 1998; 342: 367-70.
66. D'Aquila PS, Collu M, Gessa GL, Serra G. Dizocilpine prevents the enhanced locomotor response to quinpirole induced by repeated electroconvulsive shock. Eur J Pharmacol 1997; 330: 11-4.
67. Nomikos GG, Mathe AA, Mathe JM, Svensson TH. MK-801 prevents the enhanced behavioural response to apomorphine elicited by repeated electroconvulsive treatment in mice. Psychopharmacology 1992; 108: 367-70.
68. Meloni D, Gambarana C, De Montis MG, Dal Pra P, Taddei A, Tagliamonte A. Dizocilpine antagonizes the effect of chronic imipramine on learned helpleness in rats. Pharmacol Biochem Behav 1993; 46: 423-6.
69. Leander JD. Tricyclic antidepressants block N-methyl-D-aspartic acid-induced lethality in mice. Br J Pharmacol 1989; 96: 256-8.
70. Reynolds IR, Miller RJ. Tricyclic antidepressants block N-methyl-D-aspartate receptors: similarities to the action of zinc. Br J Pharmacol 1988; 95: 95-102.
71. Vamvakidès A. Effet de l'agonisme dopaminergique présynaptique sur l'immobilité des souris dans le test de la nage forcée. Ann Pharm Fr 1999; 57; 374-9.
72. Sporn J, Sachs G. The anticonvulsant lamotrigine in treatment-resistant manic-depressive illness. J Clin Psychopharmacol 1997; 17: 185-9.
73. von Wegerer J, Hesslinger B, Berger M, Walden J. A calcium antagonistic effect of the new antiepileptic drug lamotrigine. Eur Neuropsychopharmacol 1997; 7: 77-81.
74. Dietrich DE, Emrich HM. The use of anticonvulsants to augment antidepressant medication. J Clin Psychiatry 1998; 59 (Suppl 5): 51-9.
75. Barrett JR. Therapeutic potential of 5-HT2 antagonists. DN & P 1992; 5: 453-60.
76. Tortella FC, Witkin JM, Musacchio JM. Caramiphen: A non-opioid antitussive with potent anticonvulsant properties in rats. Eur J Pharmacol 1988; 155: 69-75.